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RASSF1a b s t r a c t
Background: DNA methylation is the commonest known epigenetic change that results in silencing of
tumor suppressor genes. Promoter methylation of tumor suppressor genes has the potential for early
detection of breast cancer.
Aim: Aim is to examine the potential usefulness of blood based methylation specific polymerase chain
reaction (MSP) of methylated DKK3 and RASSF1A genes in early detection of breast cancer.
Method: Methylation status of DKK3 and RASSF1 was investigated in forty breast cancer patients, twenty
fibroadenoma patients and twenty healthy ladies as control group using MSP.
Results: Methylation of DKK3 promoter was found in 22.5% of breast cancer patients, while DKK3 methy-
lation was absent in both fibroadenoma patients and control group. Similarly, methylation of RASSF1 pro-
moter was found in 17.5% of breast cancer patients and in none of fibroadenoma and control group.
Conclusion: Promoter methylation of DKK3 and RASSF1 was found in breast cancer patients while absent
in control group suggesting that tumorspecific methylation of the two genes (DKK3 and RASSF1A) might
be a valuable biomarker for the early detection of breast cancer.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
TheWorld Health Organization has ranked breast cancer (BC) as
the most common type of cancer among women. BC remains the
most invasive cancer and the first leading cause of cancer related
deaths among women worldwide [1].
Survival rates vary greatly worldwide with the lowest rates in
developing countries. These low rates can be explained mainly
by the lack of early detection programs as well as inadequate diag-
nosis and shortage of treatment facilities, resulting in a high pro-
portion of women presenting with late-stage disease [2].
Diagnosis of BC in early stage has a 5-year survival rate up to
98% [3].
Mammography has become the gold standard tool for BC
screening as it is sensitive enough to detect ductal carcinoma
in situ (DCIS). However, it has many limitations to stand alone.
The worst limitation of mammography is that clinically occult
early-stage BC is often similar in appearance to a benign breast
lesion, resulting in unnecessary subsequent biopsies [4,5].Therefore, non-invasive sensitive tests are required to comple-
ment mammography or even stand alone as a primary screening
and diagnostic tool for early detection of BC. The epigenetic mark-
ers fulfill these criteria such as methylated DNA and miRNAs since
changes in their levels have been associated with tumor burden
and malignant progression [6].
Determination of promoter methylation of tumor-suppressor
genes in the DNA of blood is a rapidly growing research field in
cancer detection. The principle of DNA methylation markers for
early BC discovery is based on evidence that growing tumors
release significant amounts of circulating DNA into bloodstream
through cellular necrosis, apoptosis, or spontaneous release of
DNA from primary and metastatic tumors [7].
DKK3 gene is a member of the human Dickkopf (Dkk) family
(WNT signaling pathway inhibitors) located on short arm of chro-
mosome 11 p15.3. The transcript length equals to 566 bps [8,9].
DKK3 expression is frequently suppressed by its promoter methy-
lation in BC [10].
Additionally, RASSF1A gene is a Ras association domain family
member 1, which is located on short arm of chromosome 3
p21.3. Methylation of the RASSF1A promoter region is the most fre-
quently described epigenetic event associated with the develop-
ment of human cancer. It occurs early in the carcinogenesis of BC
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sor function [11,12].
Therefore, in the present study, two tumor-suppressor genes
(DKK3 and RASSF1A) were investigated among Egyptian females
with BC, and comparing the results to those of fibroadenoma
patients (the most common benign breast disease) [13] and
healthy controls using methylation specific polymerase chain reac-
tion (MSP).
2. Subjects and methods
2.1. Patients
This study was carried out on 80 females; forty BC patients,
twenty fibroadenoma patients and twenty matched age healthy
ladies as control group. The study was approved by local ethics
committee. All BC patients undergo full history taking, clinical
examination, mammography and prognostic markers (proges-
terone receptors [PR], estrogen receptors [ER], and human epider-
mal growth factor receptor-2 [Her-2/neu]). The control group was
free of family history of BC. Clinicopathological parameters were
investigated in BC patients including: possible family history of
BC, the histopathology of tumor, tumor stage, lymph nodes
involvement and BC hormonal assay (ER, PR and Her-2/neu).
2.2. Determination of the methylation status of DKK3 and RASSF1A
promoters using (MSP)
Firstly, DNA was extracted from blood using QIAGEN total DNA
purification kit (QIAamp DNA Blood Mini Kit), QIAGEN, Germany.
The extracted DNA was bisulfite converted using the EZ DNA
methylation kit (Zymo Research, Orange, CA, USA). The methyla-
tion status of the promoter of DKK3 and RASSF1A genes was deter-
mined qualitatively by MSP [14]. Briefly, the bisulfite-converted
DNA was amplified using primer sets specific for both unmethy-
lated and methylated promoter sequences of DKK3 and RASSF1A
genes. 25 ll PCR mix containing 2.5 ll bisulfite-modified DNA,
1 ll forward primer, 1 ll reverse primer, 12.5 ll of Epitect MSP
master mix and 8 ll RNase free water was prepared. The previous
mix was subjected to 95 C for 10 min followed by 40 cycles of
94 C for 30 s, primer annealing at 63 C for DKK3 gene and at
55 C for RASSF1A gene for 30 s, 72 C for 30 s, and a final extension
step at 72 C for 10 min. MSP primer sequences and annealing tem-
perature are listed in Table 1. PCR amplicons were electrophoresed
on 2% agarose gels and visualized using transilluminator ultravio-
let light. Universal methylated and unmethylated control (Epi Tect
Control DNA Set, Qiagen, Germany) were included in each run. The
sample is considered to have methylated or unmethylated gene
allele depending on the primer pairs used. Consequently, sample
is considered methylated when band appears only with methy-
lated primers or unmethylated when band appears only with
unmethylated primers) or hemimethylated if bands were appeared
with both methylated and unmethylated primers; meaning that
the patient has both alleles: methylated and unmethylated.Table 1
MSP primer sequences and annealing temperature for DKK3 and RASSF1.

















Data analysis was performed using the software package SPSS
version 10.0 (SPSS, Inc., Chicago, IL, USA). ANOVA was used to ana-
lyze differences between groups. The chi-squared test is used to
determine whether there is a significant difference between the
expected frequencies and the observed frequencies in one or more
categories. Results were considered significant if the p value was
less than 0.05.
3. Results
The age of BC patients and healthy controls ranged from 28 to
61 years, and from 23 to 60 years respectively. However, fibroade-
noma patients’ age ranged from 21 to 54 years. The age of fibroade-
noma patients was significantly low with p < 0.001, that in line
with the fact that fibroadenoma is a disease of young ladies [13].
Comparing the menopausal status between the studied groups
revealed that 60% of BC patients and controls were in pre-
menopausal state, while the rest (40%) were in post-menopausal
period with no significant difference between both groups. How-
ever, most of fibroadenoma group were in pre-menopausal state
(90%) with significant difference versus BC and controls (p < 0.001).
3.1. Clinicopathological characteristics of BC
Regarding BC patients, about 37.5% of patients had positive
family history of BC. Positive ER were encountered among 57.5%
of patients, while positive PR were encountered among 30% of
cases. On the other hand, Her2/neu receptors were negative in
more than four fifths of cases (92.5%) (Table 2). Furthermore,
metastasis were found in 15% of patients varing between bone
and liver metastasis, while lymph nodes involvement were found
in 40% of cases. Regarding the stage of the tumor, 72.5% of patients
were stage II, 12.5% were stage III and about 15% of cases were
stage IV. The histopathological findings revealed that the majority
of BC (95%) had infiltrating ductal carcinoma, while 5% had infil-
trating lobular carcinoma (Table 2).
3.2. Assessment of DKK3 and RASSF1A promoter methylation using
MSP
Next, DKK3 and RASSF1A promoter methylation were assessed
in the three studied groups. DKK3 and RASSF1A methylation were
present only in BC patients [DKK3 in 9 patients (22.5%), RASSF1A
in 7 patients, (17.5%)]. Either DKK3 or RASSF1A methylation was
not detected in fibroadenoma or controls (Table 3).
Then, we studied potential associations between DKK3 and
RASSF1A promoter methylation and the clinicopathological param-
eters (Table 4). Only significant correlation between DKK3 pro-
moter methylation and distant metastasis was identified
(p = 0.041). No significant correlation was detected between
RASSF1Amethylation and any of the studied parameters e.g. family
history, tumor stage, distant metastasis (unpublished data).Annealing Temperature Cycles Product size
63 C 40 278 bp
63 C 40 276 bp
55 C 40 180 bp
55 C 40 160 bp
Table 2
Distribution of the studied BC cases according to different studied parameters.
Characteristic No. %
Family History 15 37.5
*ER positivity 23 57.5
+PR positivity 12 30.0
#HER2 positivity 3 7.5
Metastasis 6 15.0


















*Estrogen Receptor, + progesterone Receptor, # human epidermal growth factor
receptor-2.
Table 5
Sensitivity and specificity of blood-based detection of methylated DKK3 and RASSF1
genes in the three studied groups.
Gene Sensitivity in
Breast Cancer








DKK3 9 of 40 22.5% 20 of 20 100% 20 of 20 100%
RASSF1 7 of 40 17.5% 20 of 20 100% 20 of 20 100%
DKK3
&RASSF1*
16 of 40 40% 20 of 20 100% 20 of 20 100%
*Either gene methylated.
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BC patients
Methylation of DKK3was significantly associated with methyla-
tion of RASSA1 (chi-square test-p = 0.0005). Both gene promoters
were methylated in 6 patients (15%) and were unmethylated in
18 patients (45%). One patient was DKK3 methylated-RASSA1
unmethylated (2.4%) and one patient was DKK3 unmethylated-
RASSA1 methylated (2.4%)
3.4. Determination which gene is better as blood-based BC test with
qualitative MSP
Initially, the sensitivity and specificity of each gene was deter-
mined. Sensitivity of DKK3 methylation alone in BC was 22.5% (9Table 3
Comparison between the three studied groups according to the MSP results of DKK3 and
Patients (n = 40) Fibroadenoma (n = 2
No. % No. %
Result of DKK3
Unmethylated 19 47.5 10 50
Hemimethylated 12 30.0 10 50
Methylated 9 22.5 0 0.0
Result of RASSF1
Unmethylated 28 70.0 20 10
Hemimethylated 5 12.5 0 0.0
Methylated 7 17.5 0 0.0
v2: Chi square test, MC: Monte Carlo test.
*: Statistically significant at p  0.05.
Table 4
Association between the results of DKK3 gene and different studied parameters in Breast





No. % No. %
Family History 6 31.6 4 33
Positive ER 11 57.9 7 58
Positive PR 5 26.3 5 41
Positive Her2 2 10.5 1 8.
Lymph node 9 47.4 5 41
Metastasis 1 5.3 1 8.
*Estrogen Receptor, +progesterone Receptor, # human epidermal growth factor receptor
v2: Chi square test, MC: Monte Carlo test.
*: Statistically significant at p  0.05.out of 40 patients were methylated) with specificity 100% as all
fibroadenoma patients and controls were methylation negative.
Besides, RASSF1A methylation has sensitivity of 17.5% (7 out of
40 patients were methylated) with specificity 100% as the
fibroadenoma and controls showed no methylation (Table 5). Com-
bining both of DKK3 and RASSF1A methylation revealed an
improvement in the sensitivity of the panel up to 40% (16 out of
40 patients) for the detection of BC and a specificity of 100% (20
out of 20 were negative for methylation) in fibroadenoma and con-
trols (Table 5).
4. Discussion
In the present study we evaluated the performance of the pro-
moter methylation of two tumor suppressor genes i.e. DKK3 and
RASSF1A. Each gene has different role in BC pathogenesis e.g.
DKK3 isWNT signaling pathway inhibitor [8,15–17],while RASSF1A
regulates the apoptotic process. Therefore, promoter methylation
followed by silencing of the previous genes would assist in the dis-
ease carcinogensis. Here, for the first time we used qualitative MSPRASSF1 genes.
0) Control (n = 20) X2 MCp
No. %
.0 11 55.0 9.921* 0.030*
.0 9 45.0
0 0.0





Methylated (n = 9)
No. %
.3 5 55.6 1.625 0.488
.3 5 55.6 0.019 1.000
.7 2 22.2 1.157 0.669
3 0 0.0 0.866 1.000
.7 2 22.2 1.585 0.498
3 4 44.4 6.296* 0.041*
-
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Egyptian BC patients. To see the potential usefulness of both genes
in BC, we compared the results to those of both genes in most com-
mon benign breast disease (fibroadenoma) and in healthy controls.
Also, blood was used as non-invasive sample to investigate the
suitability of this technique in different stages of BC patients.
DKK3 promoter methylation was not found in either fibroade-
noma patients or controls. However, nine out of forty BC patients
(22.5%) showed methylation of DKK3. Correlating the clinicopatho-
logical parameters with DKK3 promoter methylation revealed no
association with any of the previous parameters except distant
metastasis (p = 0.041). Previously, DKK3 methylation showed sig-
nificant correlation with poor overall patients [18]. That might
indicate the useful prognostic role of DKK3 methylation in predict-
ing patient survival. Additionally, downregulation of DKK3 expres-
sion was detected in highly aggressive basal BC subtype [19].
On the other hand, methylated RASSF1A was detected in 7
patients out of the forty BC patients (17.5%), without any methyla-
tion detection in fibroadenoma patients or controls. RASSF1A pro-
moter methylation was previously detected in BC tissues and BC
cell lines [20], in plasma DNA of BC patients [21], also in serum
DNA of BC patients [22,23]. RASSF1A showed different sensitivity
and specificity in different studies which is related most probably
to number of the samples included. For instance, in a big cohort
study of 261 BCE serum, 112 paired BC tissue and 237 of cancer
free individuals showed high sensitivity of RASSF1A methylation
(47%) with quite low specificity (74%), which may indicate that
RASSF1A alone is not highly specific [15]. Opposite to DKK3,
RASSF1A did not show significant correlation with distant metasta-
sis. However, this does not exclude the association of RASSF1A
methylation with tumor progression and metastasis [24]. Given
the frequencies of RASSF1A methylation in cancer, RASSF1A was
included in our study besides DKK3 in a panel for detection of
BC. Such addition has raised the sensitivity to be 40% comparing
to sensitivity of applying each gene alone e.g. 22.5% using DKK3
and 17.5% using RASSF1A.
The epigenetic changes in cancer are very heterogeneous [25],
so using panels of more than one gene will improve the screening
procedures. Therefore, promoter methylation of the DKK3/RASSF1A
genes combination allowed significant discrimination of BC blood
from benign breast disease and control groups with sensitivity
higher than using each one alone. This panel represents a simple
and non-invasive blood based test that can complement mammog-
raphy in early detection of BC.
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